[Glucose assimilation under high-dose norethisterone-acetate therapy in adenocarcinoma of the corpus uteri].
In 29 patients suffering from adenocarcinom of the corpus uteri, who had been treated with high doses of norethisterone acetate (NEA) alone or in combination with irradiation, we performed a study in order to find out whether NEA will produce a clinically measurable and noteworthy modification of glucose tolerance. -- For this purpose, the glucose assimilation coefficient (k value), apart from its first determination, will be determined 6 weeks later under current therapy. The comparison of both values shows a statistically significant decrease of the k value after 6 weeks in all patients whose first value was k less than or equal to 1. For the patients with a first value of k greater than 1 a significant development was not detectable. The alteration of the k value under NEA therapy in patients with a primarily decreased value (n = 11; in 5 of them diabetes known) was accompanied merely by 2 diabetics with changes in the day profile of such an extent that a correction of therapy was necessary.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000368:Aged; D005260:Female; D005947:Glucose / Q000378:metabolism*; D005951:Glucose Tolerance Test; D006801:Humans; D008875:Middle Aged; D009640:Norethindrone / Q000008:administration & dosage*; D014594:Uterine Neoplasms / Q000188:drug therapy*
D005947:Glucose; D009640:Norethindrone
Glukoseassimilation unter hochdosierter Norethisteronazetattherapie beim Adenokarzinom des Corpus uteri.